Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase Ib/II trial tests the safety, side effects, best dose and how well giving CX-5461 works for the treatment of patients with B-cell non-Hodgkin lymphoma. CX-5461 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving CX-5461 may be safe, tolerable and/or effective in treating patients with B-cell non-Hodgkin lymphoma.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Rozpoznany jeden z trzech typów agresywnego chłoniaka: chłoniak podwójnie ekspresyjny, wysokoklasowy chłoniak B-komórkowy lub chłoniak Burkitta
- •Poprzednio otrzymane co najmniej dwa leczenia (dla chłoniaka dużokomórkowego) lub jedno leczenie (dla chłoniaka Burkitta), które nie działały
- •Ogólny stan zdrowia pozwalający na uczestniczenie w badaniu (ocena ECOG ≤2)
- •Prawidłowe wyniki niektórych badań krwi, w tym wystarczająca liczba białych krwinek i płytek krwi
- •Prawidłowa funkcja wątroby i nerek
- •W przypadku HIV - musi być leczony skutecznym lekiem z niezauważalnym wirusem
- •W przypadku zapalenia wątroby B - wirus musi być niedetektowalny przy leczeniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 22, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (8)
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, United States
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, United States
University of Kansas Clinical Research Center
Fairway, United States
University of Kansas Cancer Center
Kansas City, United States
University of Kansas Hospital-Indian Creek Campus
Overland Park, United States
University of Kansas Hospital-Westwood Cancer Center
Westwood, United States
University of Oklahoma Health Sciences Center
Oklahoma City, United States
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, United States
Trial contact
Site Public Contact
Nicole Foley
PRINCIPAL_INVESTIGATOR
Site Public Contact
Aung M. Tun
PRINCIPAL_INVESTIGATOR
Site Public Contact
Sami Ibrahimi
PRINCIPAL_INVESTIGATOR
Site Public Contact
Jing-Zhou Hou
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/23/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.